During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiomepost discussed with Juan Basterra, CEO at Mikrobiomik, about the interim results on MBK-01, the first intestinal microbiota-based biological drug in phase 3 for both primary episode and recurrence of Clostridioides dificile.
MBK-01, orally administered biologic medicine based in primary or recurrent Clostridiodes difficile infection
Juan Basterra, CEO at Mikrobiomik, talks about the interim results on MBK-01, the first intestinal microbiota-based biological drug in phase 3 for both primary episode and recurrence of Clostridioides dificile.
Latest related content
